The group’s principle activity is to provide cancer treatment by performing diagnostic reference laboratory and clinical research services. The group’s product includes Prostate Px(R). The group’s services include objective tumor grading, risk stratification based on disease progression , and development of companion prognostics. The group operates from United States.
